早期乳腺癌患者的前哨淋巴结活检应该被放弃吗？没那么快。
Should Sentinel Lymph Node Biopsy for Patients with Early Breast Cancer Be Abandoned? Not So Fast.
作者信息
Chu Quyen D, Peddi Prakash
机构信息
Department of Surgery, Louisiana State University Health Sciences Center, Shreveport, LA, USA.; Professor and Chief of Surgical Oncology Charles D. Knight, Sr. Endowed Professor of Surgery Director, Vice-Chair of Academic Affairs, Peritoneal Surface Malignancies Program, Feist-Weiller Cancer Center, LSU-Health Sciences Center-Shreveport, Shreveport, LA, USA.
Department of Medicine, The Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA, USA.; Assistant Professor of Medicine, Division of Hematology and Oncology, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA.
出版信息
Clin Med Insights Oncol. 2016 Jul 5;10:67-9. doi: 10.4137/CMO.S32817. eCollection 2016.
As major advances are made in the management of early breast cancer, the role of sentinel lymph node biopsy (SLNBx) has been called into question. However, before abandoning SLNBx, a critical appraisal of its role should be done because we believe that it remains a critical component of care, especially when tailoring patient's adjuvant therapy. This commentary provides cogent arguments in favor of SLNBx in the management of patients with early breast cancer.
随着早期乳腺癌治疗取得重大进展，前哨淋巴结活检（SLNBx）的作用受到了质疑。然而，在放弃前哨淋巴结活检之前，应对其作用进行批判性评估，因为我们认为它仍然是治疗的关键组成部分，尤其是在为患者量身定制辅助治疗时。本评论提供了令人信服的论据，支持在前哨淋巴结活检在早期乳腺癌患者的治疗中应用。
Zotero 插件